Trial · NCT01979393
IRCI Gynae Sarcomas, High Grade Uterine Sarcoma
NCT01979393, Phase 2, Completed, European Organisation for Research and Treatment of Cancer - EORTC
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. IRCI Gynae Sarcomas, High Grade Uterine Sarcoma. Trials, record NCT01979393. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01979393
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- IRCI Gynae Sarcomas, High Grade Uterine Sarcoma
- NCT number
- NCT01979393
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 58 participants, actual
- Lead sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Conditions
- Uterine Sarcoma
- Interventions
- Cabozantinib, Placebo
- First posted
- 2013-11-08
- Last updated
- 2025-08-01
- Other registries' IDs
- eudract:2013-000762-11
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression Free Survival (PFS) | 3.5 years from first patient in | The primary endpoint is PFS rate at 4 months after randomization to cabozantinib or placebo |
| Secondary | Progression free survival | 3.5 years from first patient in | |
| Secondary | Overall survival | 3.5 years from first patient in | |
| Secondary | Response rate | 3.5 years from first patient in | |
| Secondary | Duration of response to cabozantinib | 3.5 years from first patient in | |
| Secondary | Response rate to anthracycline-based chemotherapy for the patients with measurable disease | 3.5 years from first patient in | |
| Secondary | Assessment of global health status/QoL scale | 3.5 years from first patient in | The primary health-related quality of life endpoint that is considered of interest for this study is the global health status/QoL scale |
| Secondary | Occurence of Adverse Events | 3.5 years from first patient in | This study will use the International Common Terminology Criteria for Adverse Events (CTCAE), version 4.0, for adverse event reporting. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01979393
GET https://conductscience.org/api/trials/v1/NCT01979393/registered